切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2012, Vol. 01 ›› Issue (02) : 116 -118. doi: 10.3877/cma.j.issn.2095-3216.2012.02.011

综述

干细胞治疗肾脏病的研究进展
胡婕1, 陈香美1,()   
  1. 1.100853 北京,解放军总医院肾脏病科 全军肾脏病研究所 肾脏疾病国家重点实验室
  • 收稿日期:2012-05-30 出版日期:2012-12-18
  • 通信作者: 陈香美

Development of stem cell therapy in kidney disease

Jie HU1, Xiang-mei CHEN1,()   

  1. 1.Department of Nephrology, Kidney Institute of Chinese People's Liberation Army, State Key Laboratory of Kidney Desease, Chinese People's Liberation Army General Hospital, Beijing 100853, China
  • Received:2012-05-30 Published:2012-12-18
  • Corresponding author: Xiang-mei CHEN
引用本文:

胡婕, 陈香美. 干细胞治疗肾脏病的研究进展[J/OL]. 中华肾病研究电子杂志, 2012, 01(02): 116-118.

Jie HU, Xiang-mei CHEN. Development of stem cell therapy in kidney disease[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2012, 01(02): 116-118.

急性肾损伤和慢性肾脏病患病率高,治疗手段有限,已成为威胁人类健康的重要疾病。近年来,干细胞和再生医学的发展为肾脏疾病的治疗提供了新的手段。这些新的治疗方法包括内源性或外源性干细胞诱导器官损伤修复,或启动器官再次发育。本文阐述了外源性干细胞应用于肾脏创伤后修复的生物学研究现状,总结了目前干细胞治疗研究存在的问题及展望,为今后干细胞治疗肾脏疾病的研究提供新的思路。

The incidence of chronic kidney disease (CKD) and acute kidney injury(AKI) are increasing gradually in each year, which becomes life threatening diseases in these years because of lack of effective therapy. In recent years, stem cells and regenerative medicine may provide additional regenerative options for kidney disease. Such new treatments might involve induction of repair using endogenous or exogenous stem cells or the reprogramming of the organ to reinitiate development. This review addresses the current state of understanding with respect to exogenous stem cell therapy in the biology of normal renal repair in response to damage. It also summarizes the remaining problems and provides clues of stem cell therapy in kidney disease.

1
Hartman HA, Lai HL, Patterson LT. Cessation of renal morphogenesis in mice [J]. Dev Biol, 2007, 310(2): 379-387.
2
Cochrane AL, Kett MM, Samuel CS, et al. Renal structural and functional repair in a mouse model of reversal of ureteral obstruction [J]. J Am Soc Nephrol, 2005, 16(12): 3623-3630.
3
Vogetseder A, Karadeniz A, Kaissling B, et al. Tubular cell proliferation in the healthy rat kidney [J]. Histochem Cell Biol,2005, 124(2): 97-104.
4
Imasawa T, Nagasawa R, Utsunomiya Y, et al. Bone marrow transplantation attenuates murine IgA nephropathy: role of a stem cell disorder [J]. Kidney Int, 1999, 56(5): 1809-1817.
5
Held PK, Al-Dhalimy M, Willenbring H, et al. In vivo genetic selection of renal proximal tubules [J]. Mol Ther, 2006, 13(1): 49-58.
6
Prodromidi EI, Poulsom R, Jeffery R, et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome [J]. Stem Cells, 2006, 24(11): 2448-2455.
7
Lee VW, Wang YM, Wang YP, et al. Regulatory immune cells in kidney disease [J]. Am J Physiol Renal Physiol, 2008, 295(2):F335-342.
8
Flaquer M, Franquesa M, Vidal A, et al. Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes [J].Diabetologia, 2012, 55(7): 2059-2068.
9
Fang TC, Otto WR, Rao J, et al. Haematopoietic lineagecommitted bone marrow cells, but not cloned cultured mesenchymal stem cells, contribute to regeneration of renal tubular epithelium after HgCl 2 -induced acute tubular injury [J].Cell proliferation, 2008, 41(4): 575-591.
10
Bi B, Schmitt R, Israilova M, et al. Stromal cells protect against acute tubular injury via an endocrine effect [J]. J Am Soc Nephrol,2007, 18(9): 2486-2496.
11
Togel F, Cohen A, Zhang P, et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury [J]. Stem Cells Dev, 2009, 18(3): 475-485.
12
Gheisari Y, Ahmadbeigi N, Naderi M, et al. Stem cell-conditioned medium does not protect against kidney failure [J]. Cell Biol Int,2011, 35(3): 209-213.
13
Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury [J]. Kidney Int, 2007, 72(4): 430-441.
14
Hagiwara M, Shen B, Chao L, et al. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation [J]. Hum Gene Ther, 2008, 19(8): 807-819.
15
Huang ZY, Hong LQ, Na N, et al. Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis [J]. Cell Biochem Funct, 2012, 30(2):139-144.
16
Gheisari Y, Azadmanesh K, Ahmadbeigi N, et al. Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury [J].Stem Cells Dev, 2012, 21(16): 2969-2980.
17
Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice [J].Kidney Int, 2006, 70(1): 121-129.
18
Wise AF, Ricardo SD. Mesenchymal stem cells in kidney inflammation and repair [J]. Nephrology (Carlton), 2012, 17(1): 1-10.
19
Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression [J].Transplantation, 2010, 90(12): 1312-1320.
20
Kim D, Dressler GR. Nephrogenic factors promote differentiation of mouse embryonic stem cells into renal epithelia [J]. J Am Soc Nephrol, 2005, 16(12): 3527-3534.
21
Vigneau C, Polgar K, Striker G, et al. Mouse embryonic stem cell-derived embryoid bodies generate progenitors that integrate long term into renal proximal tubules in vivo [J]. J Am Soc Nephrol, 2007, 18(6): 1709-1720.
22
Bruce SJ, Rea RW, Steptoe AL, et al. In vitro differentiation of murine embryonic stem cells toward a renal lineage [J].Differentiation, 2007, 75(5): 337-349.
23
Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart [J]. Nature, 2008, 453(7193): 322-329.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[3] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[9] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[11] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要